Form D · Biotechnology
NEUTROLIS INC.
Cambridge, MA · CIK 0001788926
Offering snapshot reported Jul 15, 2025 · SEC filing
- Reported sold
- $3.5M Offering amount: $10M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 20, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 15, 2025 | Initial | $3,500,000 | No comparison | 1 | SEC filing |
| Apr 8, 2025 | Initial | $964,955 | No comparison | 9 | SEC filing |
| Dec 3, 2021 | Initial | $23,136,190 | No comparison | 28 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-551762
Source: Form D, filed Jul 15, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anthony Aiudi | Director, Executive, Promoter |
| Gerald Chan | Director |
| Toby Fox | Director, Executive, Promoter |
| Abdul Hakkim Rahamathullah | Director, Executive, Promoter |
| John Sundy | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Broadway, Floor 14
Cambridge, MA, 02142
Cambridge, MA, 02142